HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Prostacyclin derivatives].

Abstract
Epoprostenol (prostacyclin) has been shown to improve survival in pulmonary arterial hypertension. However, this therapy needs continuous intravenous administration devises because of its short half-life. Recently, an orally active prostacyclin analogue, beraprost sodium, and its drug delivery system have been developed in Japan. Beraprost sodium improves pulmonary hemodynamics in patients with pulmonary arterial hypertension. In addition, we have developed ONO-1301, a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Subcutaneous administration of ONO-1301 markedly attenuated monocrotaline-induced pulmonary hypertension and improved survival in rats. These prostacycline derivates may be promising for the treatment of pulmonary arterial hypertension.
AuthorsNoritoshi Nagaya
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 66 Issue 11 Pg. 2145-50 (Nov 2008) ISSN: 0047-1852 [Print] Japan
PMID19051734 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Pyridines
  • ONO 1301
  • beraprost
  • Epoprostenol
Topics
  • Epoprostenol (analogs & derivatives, therapeutic use)
  • Humans
  • Hypertension, Pulmonary (drug therapy)
  • Pyridines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: